<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Transformed <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (TL) represents a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with an aggressive course and poor prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>We assessed the clinical benefit of single-agent lenalidomide based on histological origin, including transformed follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (tFL) and transformed <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath>/small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (tCLL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Our analysis included 33 patients with TL </plain></SENT>
<SENT sid="3" pm="."><plain>Patients received lenalidomide at a median dose of 25 mg/d </plain></SENT>
<SENT sid="4" pm="."><plain>The overall response rate (ORR) was 46%, with a median response duration of 12·8 months after a median follow-up of 5·6 months </plain></SENT>
<SENT sid="5" pm="."><plain>Median progression-free survival was 5·4 months </plain></SENT>
<SENT sid="6" pm="."><plain>Among patients with tFL, ORR was 57%, with a median response duration of 12·8 months </plain></SENT>
<SENT sid="7" pm="."><plain>None of the patients with tCLL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e> responded to lenalidomide monotherapy </plain></SENT>
<SENT sid="8" pm="."><plain>The most common grade 3/4 adverse events were reversible <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Our results suggest that the original <z:hpo ids='HP_0002665'>lymphoma</z:hpo> histology (i.e. FL) in TL patients may potentially be associated with response to salvage lenalidomide monotherapy </plain></SENT>
</text></document>